News

Here you'll find the latest press releases issued by Rejuveron and its portfolio companies. Scroll down to discover more stories about our science, our business and our people. 

11.07.2022
Second Rejuveron company transitions into clinical stage as first patient is dosed in trial of Endogena Therapeutics’ novel regenerative treatment for blindness caused by retinitis pigmentosa
18.04.2022
Rejuveron CEO and Co-Founder Matthias Steger named as a 2022 In Vivo Rising Leader
28.03.2022
Rejuveron Transitions to Become a Clinical Stage Company as Rejuvenate Biomed Starts Ground-breaking Clinical Trial in Age-Related Muscle Wasting Disease, Sarcopenia
12.12.2021
Rejuveron Increases to Near-majority Stake in Endogena Through Funding $20m to Progress Treatments for Degenerative Diseases of the Eye
18.11.2021
Rejuveron Appoints Roche Veteran Bob Silverman as Chief Business Officer and Opens US Operations in New York
11.10.2021
Rejuveron leads EUR 15.7 million Series B investment in Rejuvenate Biomed to accelerate clinical development of its sarcopenia treatment for healthy aging
26.01.2021
Endogena completes 8 million financing and extends Series A round
31.12.2020
Rejuveron has moved to its new incubator space in the Bio-Technopark in Schlieren-Zürich
04.05.2022
“Aging intersects with absolutely every other aspect of human experience”
03.05.2022
“My survival instinct sparked me to get into aging research”
09.03.2022
Researchers at Rejuveron deploy knowledge gained in Nobel prize-winning techniques to crack catalysis conundrums
08.12.2021
Our sponsored feature in nature describes our vision to make therapies happen
03.11.2021
Women in Biotech - What does it take to increase gender equality in biotech?
20.07.2021
Make your research work: scientific freedom with sustainable support
19.07.2021
Make your future at Rejuveron: from valves and pipes to leading longevity discovery
14.12.2020
Rejuveron Senescence Therapeutics: Bringing senescent cells out of hiding